Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07725146

Turkish Validation of the Rapprich Lipedema Symptomatic Assessment Questionnaire

Lipedema is a chronic disease characterized by abnormal fat accumulation, primarily in the lower extremities, affecting women. This study aims to evaluate the validity and reliability of the Turkish version of the Rapprich Lipedema Symptomatic Assessment Questionnaire, which was originally developed by Rapprich et al. in 2010. Since a validated Turkish version is currently unavailable, this research will provide a standardized tool for clinicians to assess symptomatic severity in Turkish-speaking lipedema patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lipedema Connective Tissue Diseases Skin and Connective Tissue Diseases

Age range

18 year–75 year

Sex eligibility

Female

Study type

Observational

Primary location

Sultan 2. Abdülhamid Han Training and Research Hospital, Physical Medicine and Rehabilitation Clinic, Istanbul, Turkey., Istanbul, Kadıköy, Turkey (Türkiye)

Loading trial locations.

About this study

This cross-sectional study will involve 180 female participants diagnosed with lipedema (Stages I, II, and III). Participants will be recruited from the Physical Medicine and Rehabilitation clinics of Marmara University and Sultan 2. Abdülhamid Han Training and Research Hospital.

Assessments will include:

  • Demographic data (age, BMI).
  • Physical examinations (waist-hip ratio, limb circumference, and volume calculations).
  • Functional testing (6-minute walk test).
  • The Turkish version of the Rapprich Lipedema Symptomatic Assessment -Questionnaire (15 items scored 0-10).
  • The SF-36 Health Survey for criterion validity.

Statistical analysis will include Cronbach's alpha for internal consistency, Intraclass Correlation Coefficient (ICC) for test-retest reliability (14-day interval), and Exploratory/Confirmatory Factor Analysis for construct validity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female patients aged 18-75.
  • Diagnosed with lipedema by a clinician.
  • Willingness to participate and sign the informed consent form.

Exclusion criteria

  • Positive Stemmer sign or presence of advanced-stage lymphedema.
  • Diagnosis of Heart Failure.
  • Chronic Kidney Disease.
  • Pregnancy.
  • BMI > 50 kg/m².

Treatment and study plan

questionnaires

Other

Turkish version of Rapprich Lipedema Symptomatic Assessment Questionnaire: A 15-item scale used to evaluate the severity of lipedema symptoms (such as pain, tension, tenderness, bruising, and heaviness) on a 0-10 point rating scale.

Short Form-36 (SF-36) Health Survey: A widely used, validated scale to assess the general health status and quality of life across eight sub-dimensions, used in this study for criterion validity

Physical Examination and Functional Testing

Other
  • Anthropometric and Vital Measurements: Recording of demographic data (age, height, weight, BMI), as well as arterial blood pressure and pulse rate.
  • Lipedema-Specific Assessment: Clinical determination of the lipedema stage (Stages I-III) and type (Types I-V).
  • Morphometric Measurements: Measurement of waist and hip circumferences (for waist-to-hip ratio) and actual leg length.
  • Lower Extremity Volume Calculation: Circular circumference measurements taken at 4 cm intervals starting from the ankle to calculate the total volume of both lower extremities.
  • 6-Minute Walk Test (6MWT): A functional test to evaluate the total walking distance and heart rate response, assessing the patient's functional capacity.

Primary outcomes

  1. Internal Consistency (Cronbach's Alpha)

    Time frame: At baseline (Day 0).

    Evaluation of the internal consistency of the 15-item Turkish Rapprich Lipedema Questionnaire.

Secondary outcomes

  1. Test-Retest Reliability (ICC)

    Time frame: Baseline and 14 days

    Agreement between two measurements taken 14 days apart in a subgroup of 40 patients.

  2. Criterion Validity (Correlation with SF-36).

    Time frame: At baseline (Day 0)

    Correlation between Rapprich questionnaire scores and the 8 sub-dimensions of the SF-36 quality of life scale.

Study contacts

Contact information is provided by the study sponsor or research team.

Canan Şanal, Assoc. Prof.

CONTACT

[email protected]

+90 533 138 10 32

M. Selim Eryılmaz, Res. Asst.

CONTACT

Sponsors and collaborators

Lead sponsor

Marmara University

Other

Registry information

Official study title

Turkish Validity and Reliability of the Rapprich Lipedema Symptomatic Assessment Questionnaire

Acronym: RapprichTR

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 24, 2026
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.